With drug prices on the rise, more affordable copies of brand-name drugs play an important role in the market. This section offers content pertaining to the manufacturing, regulatory and market challenges faced by generics, as well as their biologic counterparts, biosimilars.


Michael Annino/Shutterstock AI

Mining pharma's reshoring rush

It’s time for the U.S. to sift through domestic drug manufacturing efforts

Charting a sustainable path for generics

Key takeaways from the Association for Accessible Medicines’ Access! 2024 meeting
Pm22 Hero 854x480 Web

Assuring generic access evermore

Generics’ longevity hinges on steady, straightforward storytelling
Pm2303 Hero 854x480 Cover Story

Nevertheless, they persisted

How drugmakers are fighting to keep reproductive health drugs available, safe and legal

Another brick in the fall: Pharma’s biggest hit is granting licenses to patents

Music wouldn’t be quite as interesting without the legal histrionics of rock bands.In addition to having one of the best-selling albums in U.S. history, Pink Floyd is also known...

Drug deals: Casting the role of the ‘bad guy’

When headlines began calling out the “largest cartel in the history of the United States,” people kept reading

Legal unease

How the generics industry is adjusting as the dust settles on price-fixing lawsuits

Global Dose: Focus on Australia

While the R&D and clinical world has stayed on the cutting edge of modern medicine, the country’s manufacturing industry has slipped through the cracks of Australia’s economy...

10 major drugs falling off the patent cliff in 2021

At some point, the patent cliff claims the high-rolling life of market exclusivity for all drugs — and 2021 is, of course, no exception.Although the industry has been flushed ...